Suppr超能文献

1微克促肾上腺皮质激素能否用于评估危重症患者的肾上腺功能不全?

Can 1 microg of cosyntropin be used to evaluate adrenal insufficiency in critically ill patients?

作者信息

Kozyra Elizabeth F, Wax Randy S, Burry Lisa D

机构信息

Medical-Surgical ICU, Mount Sinai Hospital, Toronto, Ontario, Canada.

出版信息

Ann Pharmacother. 2005 Apr;39(4):691-8. doi: 10.1345/aph.1E139. Epub 2005 Mar 1.

Abstract

OBJECTIVE

To evaluate the utility of cosyntropin 1 microg in assessing adrenal function in critically ill patients.

DATA SOURCES

A computerized literature search using MEDLINE, EMBASE, International Pharmaceutical Abstracts, and the Cochrane Database (1966-August 2004) was undertaken for trials evaluating cosyntropin 1 mug using the following search terms: adrenocorticotropin-releasing hormone (ACTH), cosyntropin, adrenal insufficiency, cortisol, corticosteroids, glucocorticoids, sepsis, septic shock, diagnosis, critically ill, intensive care, and critical care. STUDY SELECTION AND DATA SYNTHESIS: Identifying patients with sepsis with relative adrenal insufficiency (AI) using cosyntropin testing may identify those likely to benefit from corticosteroids. The results of 5 heterogeneous studies in non-intensive care unit (ICU) patients suggest that both 1 microg and 250 microg of cosyntropin stimulate similar cortisol responses and that testing using both doses correlates well with results from insulin tolerance testing. Some data from non-ICU patients suggest that the 1-microg test may be more sensitive to detect AI; 3 heterogeneous studies in ICU patients confirmed the improved sensitivity of the 1-microg test.

CONCLUSIONS

Use of cosyntropin 1 microg should detect AI in all patients who would have been diagnosed using 250 microg. Unfortunately, all of the clinical trials evaluating the role of corticosteroids in septic shock that used the cosyntropin stimulation test administered 250 microg. Extrapolation of the existing guidelines to treat patients with septic shock testing positive for relative AI using the 1-microg test may provide effective therapy to appropriate patients not diagnosed by the 250-microg testing or may introduce additional adverse effects in patients who should not receive corticosteroids. Large-scale, head-to-head comparison data of steroid effectiveness after 1- and 250-microg ACTH stimulation tests are needed to expand upon these promising results.

摘要

目的

评估1微克促肾上腺皮质激素(cosyntropin)在评估危重症患者肾上腺功能中的效用。

资料来源

利用MEDLINE、EMBASE、国际药学文摘数据库及考克兰数据库(1966年至2004年8月)进行计算机文献检索,以查找使用以下检索词评估1微克促肾上腺皮质激素的试验:促肾上腺皮质激素释放激素(ACTH)、促肾上腺皮质激素、肾上腺功能不全、皮质醇、皮质类固醇、糖皮质激素、脓毒症、脓毒性休克、诊断、危重症、重症监护及危重症护理。研究选择与资料综合:使用促肾上腺皮质激素试验识别出患有相对肾上腺功能不全(AI)的脓毒症患者,可能会找出那些可能从皮质类固醇治疗中获益的患者。5项针对非重症监护病房(ICU)患者的异质性研究结果表明,1微克和250微克的促肾上腺皮质激素刺激产生的皮质醇反应相似,且两种剂量的检测结果与胰岛素耐量试验结果高度相关。一些来自非ICU患者的数据表明,1微克试验在检测AI方面可能更敏感;3项针对ICU患者的异质性研究证实了1微克试验具有更高的敏感性。

结论

使用1微克促肾上腺皮质激素应能检测出所有使用250微克促肾上腺皮质激素可诊断出的AI患者。遗憾的是,所有评估皮质类固醇在脓毒性休克中作用的临床试验均使用了250微克的促肾上腺皮质激素刺激试验。将现有指南外推至使用1微克试验检测相对AI呈阳性的脓毒性休克患者,可能会为未被250微克试验诊断出的合适患者提供有效治疗,也可能会给不应接受皮质类固醇治疗的患者带来额外不良反应。需要大规模的、1微克和250微克促肾上腺皮质激素刺激试验后类固醇疗效的直接对比数据,以拓展这些有前景的结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验